Malvern Panalytical and Concept Life Sciences announced a full business integration. The integration will expand the existing analytical instrument and service relationship (Amplify Analytics) to include the Chemistry and Biology services of CLS. Both entities are operating businesses within the Spectris plc Group.
The ‘Amplify Analytics’ platform offers a new range of flexible services which enables pharmaceutical firms to speed up and de-risk drug development. The move also brings together Malvern Panalytical’s physicochemical characterisation expertise and Concept Life Sciences’ bespoke chemistry and analytical services.
Mark Fleiner has succeeded Paolo Carmassi as Malvern Panalytical’s new President. Earlier, Fleiner held the post of Business Group Director – Industrial Solutions Division of Spectris where he was responsible for seven operating companies.
The new partnership between Malvern Panalytical and Concept Life Sciences is expected to develop and deploy accredited physicochemical analysis techniques and methods in the pharmaceutical and food industries. Malvern Panalytical’s knowledge of analytical instrumentation and Concept Life Sciences' method validation and support expertise is anticipated to assist this development.
Das neue Röntgenfluoreszenz-Spektrometer der Epsilon-1-Familie wurde von Panalytical gezielt für die Punktanalyse entwickelt und ist nach eigenen Angaben das leistungsstärkste Tisch-Spektrometer seiner Klasse.